Georg Karpel-Massler, M.D., Ph.D.

Address

Department of Neurosurgery

Ulm Universty Medical Center

Albert-Einstein-Allee 23

D-89081 Ulm

Germany

 

Phone: +49-731-5000

FAX: +49-731-55056

 

georg.karpel@uniklinik-ulm.de

georg.karpel@gmail.com

Education and Training

MD, 2005 - Ruprecht-Karls-University, Heidelberg, Germany

 

2005-2008 Residency in Neurosurgery - Ruprecht-Karls-University, Heidelberg, Germany

 

2008-2012 Residency in Neurosurgery - Ulm University Medical Center, Ulm, Germany

 

2012 Board certification for Neurosurgery (German Board of Neurosurgeons)

 

2012-2014 Staff Neurosurgeon - Ulm University Medical Center, Ulm, Germany

 

2014-2015 Postdoctoral research fellowship, Columbia University Medical Center (Siegelin/Greene Labs)

 

2015-2016 Assistant Clinical Professor, Department of Pathology & Cell Biology, Columbia University Medical Center

 

2016 Habilitation 

 

2017 ECFMG Certification

Memberships

European Association of Neurosurgical Societies

 

American Association for Cancer Research

Research Summary

My research focuses on developing novel therapeutic strategies for the treatment of patients with cancer. In particular, I have a profound interest in adult and pediatric neuro-oncological diseases with a special emphasis on a malignant brain tumor termed glioblastoma. 

I am striving for a better understanding of the biology of malignant diseases such as glioblastoma and to learn how to overcome therapeutic resistance. The diversity of different dysregulated tumor-driving pathways within the same tumor represents one of the central characteristics responsible for the fact that solid tumors are so difficult to treat. Considering this premise, it seems unlikely that one reagent that targets one dysregulated oncogenic pathway only, will suffice for an efficient treatment of cancerous diseases such as glioblastoma. 

Therefore, my work focuses on combining multiple reagents targeted at different aspects of oncogenic signaling to ultimately allow for a better tumor control and eventually even to overcome these diseases. 

Selected Publications

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitzes for apoptosis in vitro and in vivo. Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016, 7:33512-28

 

A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anticancer activity against a broad spectrum of treatment-resistant cancers. Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Siegelin MD. Clin Cancer Res. 2016, 22:4698-711.

 

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Karpel-Massler G, Banu MA, Shu C, Halatsch M-E, Westhoff M-A, Bruce JN, Canoll P, Siegelin MD. Oncotarget. 2016, 7:12791-805

 

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Karpel-Massler G, Ba M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD. Oncotarget. 2015, 6:36456-71

 

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Karpel-Massler G, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, Ramirez Y, Ross AH, Bruce JN, Canoll P, Siegelin MD. Oncotarget. 2015, 6:14507-21

 

Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect. Karpel-Massler G, Kast RE, Westhoff M- A, Dwucet A, Welscher N, Nonnenmacher L, Hlavac M, Siegelin MD, Wirtz CR, Debatin K-M, Halatsch M- E. Journal of Neuro-Oncology. 2015, 122:21-33

 

PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff M-A, Halatsch M-E, Crary JF, Canoll P, Siegelin MD. Plos one. 2014, 9:e114583

 

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Halatsch M-E, Karpel-Massler G, Kast RE. Oncotarget. 2014, 5:8052-82

 

Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Karpel-Massler G, Westhoff M-A, Zhou S, Nonnenmacher L, Dwucet A, Kast R-E, Bachem MG, Wirtz CR, Debatin K-M, Halatsch M-E. Mol Cancer Ther. 2013, 12:1-13 

Honors and Awards

2016 - European Association of Neurosurgical Societies Observership Award

 

2014 - Postdoctoral Scholarship, Dr. Mildred Scheel Foundation, German Cancer Aid

 

2012 - Young Investigator’s Award Ulm Medical School, Germany
 

2002 - Erasmus-Stipend

 

2001 - Stipend of the Henry M. Jackson Foundation 

Druckversion Druckversion | Sitemap
© Georg Karpel-Massler